What is the primary impact of the amendment on the QIAGEN acquisition for Thermo Fisher?

The primary impact is an increased offer price for QIAGEN shares and a lowered acceptance threshold, making the acquisition more likely to succeed. However, it also means Thermo Fisher will pay more for QIAGEN, and there's a possibility of receiving a termination fee if certain conditions aren't met, but the overall goal is to close the deal.

Why was the tender offer period extended?

The tender offer period was extended by two weeks to allow for the amended offer terms to be properly communicated and processed under applicable securities laws, particularly the German Securities Acquisition and Takeover Act. The new expiration date for the acceptance period is August 10, 2020.

What happens if the minimum acceptance threshold is not met after the amendment?

If the minimum acceptance threshold of 66.67% is not satisfied by the end of the acceptance period, QIAGEN has agreed to pay Thermo Fisher an expense reimbursement payment of $95 million in cash. This acts as a form of compensation for Thermo Fisher's efforts and expenses related to the tender offer.

Where can I find more detailed information about the amended tender offer?

More detailed information can be found in the amended tender offer materials, including the offer document, which are available on the SEC's website (www.sec.gov), QIAGEN's investor relations website (corporate.qiagen.com/investor-relations), and Thermo Fisher's investor relations website (ir.thermofisher.com). You can also contact the investor relations departments of either company or Thermo Fisher's information agent, D.F. King & Co., Inc.

TMO 8-K: Material Agreements

Summary

Thermo Fisher Scientific Inc. (TMO) has filed an 8-K report on July 16, 2020, detailing significant amendments to its previously announced Business Combination Agreement with QIAGEN N.V. The core of this amendment involves an increase in the tender offer price for QIAGEN shares from EUR 39.00 to EUR 43.00 per share. Additionally, the minimum acceptance threshold has been lowered from 75% to 66.67% of QIAGEN's outstanding ordinary share capital, making the acquisition more attainable. These changes necessitate an extension of the tender offer acceptance period by two weeks, now set to expire on August 10, 2020. The amendment also includes a provision for QIAGEN to pay Thermo Fisher a $95 million expense reimbursement under specific conditions if the minimum acceptance threshold is not met. Investors should note that this amendment impacts the financial terms and conditions of the proposed acquisition, potentially increasing Thermo Fisher's investment while also improving the likelihood of deal completion.

Key Highlights

1Thermo Fisher increased its tender offer price for QIAGEN shares from EUR 39.00 to EUR 43.00 per share.
2The minimum acceptance threshold for the tender offer has been reduced from 75% to 66.67%.
3The tender offer acceptance period has been extended by two weeks, now expiring on August 10, 2020.
4QIAGEN may be required to pay Thermo Fisher a $95 million expense reimbursement under certain conditions if the minimum acceptance threshold is not met.
5The amendment is intended to facilitate the completion of the acquisition of QIAGEN.
6Detailed tender offer materials, including the amended offer document, are available on SEC's website and QIAGEN's investor relations website.

THERMO FISHER SCIENTIFIC INC. 8-K Report, Material Agreement (Jul 16, 2020)

Summary

Key Highlights

Frequently Asked Questions